FRA
TVRD

Front Row Advisors’s Tvardi Therapeutics TVRD Stock Holding History

Front Row Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$4 – 576
2025
Q4 		$4 Hold
1
– – ﹤0.01% 552
2025
Q3 		$39 Hold
1
– – ﹤0.01% 545
2025
Q2 		$23 Sell
1
-1
-50% -$24 ﹤0.01% 531
2025
Q1 		$30 Hold
2
– – ﹤0.01% 505
2024
Q4 		$37 Hold
2
– – ﹤0.01% 496
2024
Q3 		$25 Hold
2
– – ﹤0.01% 498
2024
Q2 		$21 Hold
2
– – ﹤0.01% 936
2024
Q1 		$73 Hold
2
– – ﹤0.01% 919
2023
Q4 		$59 Hold
2
– – ﹤0.01% 467
2023
Q3 		$134 Hold
2
– – ﹤0.01% 905
2023
Q2 		$0 Hold
2
– – ﹤0.01% 962
2023
Q1 		$0 Buy
+2
New +$670 ﹤0.01% 964

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $361M AUM 18% 1-Year Est. Return

Front Row Advisors's TVRD Position: Q1 2026 in Review

Front Row Advisors sold out of Tvardi Therapeutics (TVRD) in Q1 2026, closing a stake of 1 share — an estimated $4 sold.

Front Row Advisors first reported a position in TVRD in Q1 2023 and held it in 12 quarters. The position peaked at $134 in Q3 2023. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • Front Row Advisors reported no remaining Tvardi Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Front Row Advisors sold 1 Tvardi Therapeutics share in Q1 2026, an estimated $4.
  • Front Row Advisors first reported a position in Tvardi Therapeutics in Q1 2023 and held it in 12 quarters.
  • Front Row Advisors's Tvardi Therapeutics position peaked at $134 in Q3 2023.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Front Row Advisors's 13F filing for Q1 2026, filed 19 May 2026.